A new portfolio of stocks I started building on September 8, at a one stock per week pace for the next year, is named Vista.  I will select its fifth stock this coming weekend. Vista is the sixth portfolio I've built (at a one dividend dog per-week pace) since 2014. Six portfolios = VI for Vista!

Vista is planned to Look Ahead for Outstanding, Proven, Dividend Winners. (Like Aristocrats)

Today we'll review the fifth of five healthcare sector stock candidates vying to be the fifth selection for the Vista portfolio.

My subject today is another large-cap drug manufacturer general, Pfizer Inc. Its trading ticker symbol is PFE. This is my first report on Pfizer Inc for this Vista dog of the week portfolio. I have reviewed it for my other portfolios, and selected it for each, however.  

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of over $50 billion.

Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. 

Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. 

Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.

It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. 

The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; and a multi-target drug discovery collaboration with Sosei Group Corporation. 

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

I use three key data points to gauge dividend equities or funds like Pfizer Inc:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether a company has made, is making, and will make money. 

PFE Price

Pfizer's price per share closed at $36.90 yesterday. A year ago its price was $35.69. Price rose $1.21 or just about 3.4% last year.

If Pfizer's stock trades in the range of $28 to $48 this next year, its recent $36.90 price might rise by $3.10 to reach $40.00 by October 9, 2021. 

PFE Dividends

Pfizer's most recently declared quarterly dividend was $0.38 paid on September 1st. Dividends are estimated to total $1.52 per share annually and yield 4.12% at yesterday's $36.90 closing price.

PFE Gains?

Adding the $1.52 annual anticipated dividend to my $3.10 optimistic estimate of Pfizer's price upside shows a $4.62 potential gross gain, per share, to be reduced by any costs to trade the shares.  

If we put a little under $1,000.00 today in Pfizer Inc at $36.90, we would buy 27 shares of PFE stock.

A $10 broker fee paid half at purchase and half at sale could cost us  $0.37 per share.

Subtract that $0.37 brokerage cost from my estimated $4.62 gross gain per share results in a net gain of $4.25 X 27 shares = $114.75 for an 11.5% net gain on a $996.30 investment.

So it goes that Pfizer Inc shows a possible 11.5% net gain including a 4.12% dividend yield. It could be more, it could be less.       

All of the estimates above are speculation based on the past history of Pfizer Inc. Only time and money invested in this stock will determine its worth